131 related articles for article (PubMed ID: 35081567)
21. Span-1 and CA19-9 as Predictors of Early Recurrence and Lymph Node Metastasis for Patients with Invasive Pancreatic Cancer after Pancreatectomy.
Shimizu T; Asakuma M; Tomioka A; Inoue Y; Hirokawa F; Hayashi M; Uchiyama K
Am Surg; 2018 Jan; 84(1):109-113. PubMed ID: 29428036
[TBL] [Abstract][Full Text] [Related]
22. Failure of normalization of CA19-9 following resection for pancreatic cancer is tantamount to metastatic disease.
Abdel-Misih SR; Hatzaras I; Schmidt C; Saab TB; Klemanski D; Muscarella P; Melvin WS; Ellison EC; Bloomston M
Ann Surg Oncol; 2011 Apr; 18(4):1116-21. PubMed ID: 21042945
[TBL] [Abstract][Full Text] [Related]
23. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.
Aldakkak M; Christians KK; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Evans DB; Tsai S
HPB (Oxford); 2015 Oct; 17(10):942-52. PubMed ID: 26255895
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy.
Tsutsumi K; Kawamoto H; Hirao K; Sakakihara I; Yamamoto N; Noma Y; Fujii M; Kato H; Ogawa T; Ishida E; Kuwaki K; Nouso K; Okada H; Yamamoto K
Pancreatology; 2012; 12(5):409-16. PubMed ID: 23127528
[TBL] [Abstract][Full Text] [Related]
25. The prognostic value of CA19-9 response after neoadjuvant therapy in patients with pancreatic cancer: a systematic review and pooled analysis.
Ye C; Sadula A; Ren S; Guo X; Yuan M; Yuan C; Xiu D
Cancer Chemother Pharmacol; 2020 Dec; 86(6):731-740. PubMed ID: 33047181
[TBL] [Abstract][Full Text] [Related]
26. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer.
Tsai S; George B; Wittmann D; Ritch PS; Krepline AN; Aldakkak M; Barnes CA; Christians KK; Dua K; Griffin M; Hagen C; Hall WA; Erickson BA; Evans DB
Ann Surg; 2020 Apr; 271(4):740-747. PubMed ID: 30312198
[TBL] [Abstract][Full Text] [Related]
27. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer.
Liu L; Xu H; Wang W; Wu C; Chen Y; Yang J; Cen P; Xu J; Liu C; Long J; Guha S; Fu D; Ni Q; Jatoi A; Chari S; McCleary-Wheeler AL; Fernandez-Zapico ME; Li M; Yu X
Int J Cancer; 2015 May; 136(9):2216-27. PubMed ID: 25273947
[TBL] [Abstract][Full Text] [Related]
28. DUPAN-2 as a Risk Factor of Early Recurrence After Curative Pancreatectomy for Patients With Pancreatic Ductal Adenocarcinoma.
Sasaki A; Sakata K; Nakano K; Tsutsumi S; Fujishima H; Futsukaichi T; Terashi T; Ikebe M; Bandoh T; Utsunomiya T
Pancreas; 2023 Feb; 52(2):e110-e114. PubMed ID: 37523601
[TBL] [Abstract][Full Text] [Related]
29. Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients.
Kanda M; Fujii T; Takami H; Suenaga M; Inokawa Y; Yamada S; Nakayama G; Sugimoto H; Koike M; Nomoto S; Kodera Y
Surg Today; 2014 Sep; 44(9):1692-701. PubMed ID: 24114022
[TBL] [Abstract][Full Text] [Related]
30. Elevated Preoperative DUPAN-2 Level Predicts Locoregional Recurrence After Pancreatectomy in Patients With Pancreatic Ductal Adenocarcinoma.
Sasaki A; Inokuchi S; Tsutsumi S; Futsukaichi T; Terashi T; Ikebe M; Bandoh T; Utsunomiya T
Anticancer Res; 2022 Apr; 42(4):2071-2078. PubMed ID: 35347030
[TBL] [Abstract][Full Text] [Related]
31. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicenter case-control study of 240 patients.
Aoki S; Motoi F; Murakami Y; Sho M; Satoi S; Honda G; Uemura K; Okada KI; Matsumoto I; Nagai M; Yanagimoto H; Kurata M; Fukumoto T; Mizuma M; Yamaue H; Unno M;
BMC Cancer; 2019 Mar; 19(1):252. PubMed ID: 30898101
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
33. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer.
Yagyu T; Saito H; Sakamoto T; Uchinaka EI; Morimoto M; Amisaki M; Watanabe J; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2019 Mar; 39(3):1441-1446. PubMed ID: 30842180
[TBL] [Abstract][Full Text] [Related]
34. Serum CA19-9 Response to Neoadjuvant Therapy Predicts Tumor Size Reduction and Survival in Pancreatic Adenocarcinoma.
Al Abbas AI; Zenati M; Reiser CJ; Hamad A; Jung JP; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2020 Jun; 27(6):2007-2014. PubMed ID: 31898105
[TBL] [Abstract][Full Text] [Related]
35. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
Ono Y; Inoue Y; Ito H; Sasaki T; Takeda T; Ozaka M; Sasahira N; Hiratsuka M; Matsueda K; Oba A; Sato T; Saiura A; Takahashi Y
HPB (Oxford); 2023 Jan; 25(1):100-108. PubMed ID: 36280425
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer.
Asaoka T; Miyamoto A; Maeda S; Tsujie M; Hama N; Yamamoto K; Miyake M; Haraguchi N; Nishikawa K; Hirao M; Ikeda M; Sekimoto M; Nakamori S
Pancreatology; 2016; 16(3):434-40. PubMed ID: 26852169
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study.
Miyata T; Hayashi H; Yamashita YI; Matsumura K; Nakao Y; Itoyama R; Yamao T; Tsukamoto M; Okabe H; Imai K; Chikamoto A; Ishiko T; Baba H
Ann Surg Oncol; 2021 Mar; 28(3):1572-1580. PubMed ID: 32804325
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
39. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
40. CA19-9 Change During Neoadjuvant Therapy May Guide the Need for Additional Adjuvant Therapy Following Resected Pancreatic Cancer.
Liu H; Zenati MS; Rieser CJ; Al-Abbas A; Lee KK; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2020 Oct; 27(10):3950-3960. PubMed ID: 32318949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
